Skip Navigation

Nephrology Dialysis Transplantation 2005 20(3):585-590; doi:10.1093/ndt/gfh638
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DeLong, M.
Right arrow Articles by Lien, Y.-H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeLong, M.
Right arrow Articles by Lien, Y.-H. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org


Original Article

Renin–angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance

Michael DeLong, Joy L. Logan, Kim-Chong Yong and Yeong-Hau H. Lien

Renal Section, Department of Medicine, University of Arizona, Tucson, AZ, USA

Correspondence and offprint requests to: Joy L. Logan, Department of Medicine, Renal Section, PO Box 245022, Arizona Health Sciences Center, 1501 N. Campbell Ave., Tucson, AZ 85724, USA. E-mail: jllogan{at}email.arizona.edu

Background. There are conflicting reports about the importance of the renin–angiotensin system (RAS) on erythropoietin (Epo) sensitivity in haemodialysis patients, but the role of gender has not been studied specifically. The hypothesis underlying this study is that Epo resistance associated with RAS blockade (RASB) is specific to men and related to drug-induced lowering of circulating testosterone.

Methods. Men and women undergoing chronic haemodialysis were divided into groups according to whether or not they were receiving RASB. Serum was collected pre-dialysis for determination of free testosterone levels by enzyme immunoassay. Routine laboratory data and Epo doses were collated and analysed for the 3 month period prior to the measurement of the hormone level.

Results. Control women required more Epo than control men (P = 0.002), but the Epo doses between men and women with RASB were similar. Men with RASB required more Epo than control men (P = 0.002), but RASB had no effect on Epo requirements in women. There was a significant relationship between age and testosterone levels in control men (P = 0.01) that was not present in men taking RASB. RASB was associated with lower levels of serum testosterone in men <60 years old (P = 0.02), but had no effect on serum testosterone levels in older men or women. Multiple regression analysis demonstrated that serum testosterone negatively correlated with Epo dose (P = 0.045) when all groups of patients were considered together.

Conclusions. These data suggest that androgens may participate in Epo resistance associated with RASB in patients on haemodialysis, and that the effect is related to both gender and age.

Keywords: anaemia; erythropoietin; haemodialysis; renin–angiotensin system; testosterone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ther Adv Cardiovasc DisHome page
H. Suzuki
Therapeutic efficacy of renin--angiotensin blockade in patients receiving dialysis
Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 397 - 405.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.